The Duration And Safety Of Osteoporosis Treatment

Providing a comprehensive review of short-and long-term adverse events of both antiresorptive and anabolic drugs, this practical guide updates the clinician on the pathophysiology of osteoporosis and the principles behind our present and future pharmaceuticals. Leading practitioners in the field examine all current literature and data regarding the duration and safety of these therapies, with recommendations for clinicians on decision-making and best practices for osteoporosis patients. An overview of the pathophysiology and epidemiology of osteoporosis and discussion of both anabolic and antiresorptive drugs is followed by fracture risk assessment and an examination of treatment failures. Next, a number of chapters are dedicated to the diagnosis, presentation and management of atypical femur fractures and osteonecrosis of the jaw (ONJ), each of which are significant patient concerns when using these osteoporosis treatments. The introduction and utilization of drug holidays is also discussed, as well as the long-term outlook for management of osteoporotic patients. Written and edited by experts in the field, The Duration and Safety of Osteoporosis Treatment is a balanced resource for researchers, practitioners and policy-makers alike for clinical decision-making and patient care.

Since the publication of the first edition, the U.S. Surgeon General released the first-ever report on bone health and osteoporosis in October 2004. This report focuses even more attention on the devastating impact osteoporosis has on millions of lives. According to the National Osteoporosis Foundation, 2 million American men have osteoporosis, and another 12 million are at risk for this disease. Yet despite the large number of men affected, the lack of awareness by doctors and their patients puts men at a higher risk that the condition may go undiagnosed and untreated. It is estimated that one-fifth to one-third of all hip fractures occur in men. This second edition brings on board John Bilezikian and Dirk Vanderschueren as editors with Eric Orwoll. The table of contents is more than doubling with 58 planned chapters. The format is larger – 8.5 x 11. This edition of Osteoporosis in Men brings together even more eminent investigators and clinicians to interpret developments in this growing field, and describe state-of-the-art research as well as practical approaches to diagnosis, prevention and therapy. Brings together more eminent investigators and clinicians to interpret developments in this growing field Describes state-of-the-art research as well as practical approaches to diagnosis, prevention and therapy There is no book on the market that covers osteoporosis in men as comprehensively as this book

This book responds to the daily needs of all clinicians treating patients with osteoporosis and provides a key reference guide for any challenges that arise in clinical practice. This book also covers the genetics of the disease, clinical presentation, diagnosis, and current and upcoming treatment recommendations in accordance with the latest international guidelines. Osteoporosis is a disease in which the density and quality of bone are greatly reduced, and as bones become more porous and fragile the risk of fracture increases greatly. It is one of the most common metabolic bone diseases globally with one in three women and one in five men at risk of an osteoporotic fracture, and can result in devastating physical, psychosocial, and economic consequences. However, in spite of this osteoporosis can often be overlooked and undertreated, thus there is a real need to raise awareness of this disease.

Until recently considered an inevitable part of aging, osteoporosis is typically diagnosed only after a serious complication such as a fracture. It is now possible, however, to diagnose high-risk patients beforehand. Easily performed noninvasive tests estimate bone mass, and patients at risk can be treated with new drugs whose efficacy for fracture reduction has been proven in clinical trials. Osteoporosis: An Evidence-Based Guide to Prevention and Management, the newest volume in the acclaimed ACP Women's Health series, addresses every important facet of this common disease. The latest scientific evidence and the extensive clinical experience of the authors provide essential information on the origins and progress of osteoporosis. Treatment options are thoroughly reviewed.

Put the authority of Goodman & Gilman's in the palm of your hand! 5 STAR DOODY'S REVIEW! "...the most authoritative and trusted source of pharmacological information, has now spawned a portable pocket drug guide....This manual extracts the essential core drug information from the eleventh edition of the parent book, referring the reader to the online version of the parent book for historical aspects, many chemical and clinical details, and additional figures and references. This makes G & G a very useful book. This will be of use to individuals in training or practice in the fields of pharmacy, medicine, nursing, or allied health disciplines where knowledge of drug actions are important....Each chapter provides the core essential information provided in the parent book in a very readable format. Readers can use this easy to handle and read manual for essential information along with the online version of the parent book as a reference for more in-depth specific information on drugs."--Doody's Review Service The Goodman & Gilman Manual of Pharmacology and Therapeutics offers the renowned content of Goodman & Gilman's Pharmacological Basis of Therapeutics, Eleventh Edition, condensed into an ultra-handy, streamlined reference. More than just a pocket drug guide, this indispensable resource offers: A carry-along source of essential fundamental information, with all the authority of Goodman & Gilman's Pharmacological Basis of Therapeutics, Eleventh Edition The benefits of the world's leading pharmacology text in a convenient, portable format Comprehensive, yet streamlined and clinically relevant coverage of the pharmacological basis of therapeutics High-yield overview of pharmacokinetics, pharmacodynamics, and the foundations of pharmacology Expert insights into the properties, mechanisms, and uses of all the major drug classes Considerations of vital patient-specific issues

Osteoporosis, a growing epidemic among women in North America, Europe, and Japan, is a painful, costly disease that has presented a treatment challenge to healthcare professionals. Until recently, therapies have focused on agents that slow bone resorption, and have had only limited success at increasing bone mass. However, exciting new developments are on the verge of changing the treatment of this debilitating disorder. Two anabolic agents, the parathyroid hormone (PTH) and the fluoride ion, show tremendous promise as tools for building and retaining bone - with no adverse side effects. Anabolic Treatments for Osteoporosis is a comprehensive account of the latest studies that have been carried out on these two agents, and a thorough assessment of their prospects as osteoporosis therapeutics. This unique book combines basic science and up-to-date clinical data to present a complete picture of this breakthrough in the treatment of a globally significant health issue.

This book represents a comprehensive, clinically oriented text covering all aspects of male osteoporosis, from the basic concepts of bone physiology and regulation of bone remodeling in men, the causes and pathophysiological mechanisms responsible for the most frequent causes of osteoporosis, to diagnostic and screening protocols, as well as prevention and treatment approaches. It offers a broad overview of male osteoporosis by specialists involved in research and clinical practice and discusses the practical issues encountered. Filling a gap in the literature, this volume is a valuable resource for general practitioners, clinical endocrinologists, geriatricians and experts in osteoporosis.

Osteoporosis is one of the most clinically relevant disabling chronic disease encountered in clinical practice. A common cause of osteoporosis is glucocorticoid excess, as glucocorticoids may increase bone resorption, inhibit bone formation, have indirect actions on bone by decreasing intestinal calcium absorption and induce hypercalciuria. This book presents a comprehensive overview of the effects of glucocorticoids on bone metabolism and structure and on the diagnosis and treatment of glucocorticoid-induced osteoporosis. It aims at providing updated information on the pathogenesis, diagnosis and treatment of this often dramatic complication of glucocorticoid excess. Being one of the few publications completely devoted to glucocorticoid-induced osteoporosis it will heighten the awareness of specialists who prescribe glucocorticoids of the clinical relevance of this treatment complication. 'Glucocorticoid-Induced Osteoporosis' is addressed to clinical experts as well as to general practitioners who will both benefit from the comprehensive and integrative view of the management of patients exposed to glucocorticoids.